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AN ALTERNATIVELY SPLICED TRANSCRIPT OF ADAMTS4 IN HUMAN
OSTEOARTHRITIS SYNOVIUM
S.D. Wainwright1, J. Bondeson2, C. Hughes1, B. Caterson1
1Cardiff Sch. of BioSci., Cardiff, United Kingdom; 2Dept. of Rheumatology,
Cardiff University, United Kingdom
Purpose: To describe and characterize a newly discovered alternatively
spliced transcript of the ADAMTS4 aggrecanase.
Methods: Human OA synovium was digested and synovial cell cultures
established. RT-PCR analysis was performed using oligonucleotide primers
designed to amplify across the exon 8/9 region of human ADAMTS4. RT-PCR
was performed and PCR products puriﬁed using a QIAquick puriﬁcation kit
(Qiagen) and sequenced using in house facilities.
A pCEP4 (Invitrogen) mammalian expression vector containing ADAMTS4
plus a FLAG epitope was mutated using QuikChange II site directed muta-
genesis kit (Stratagene) to contain the ADAMTS4 splice variant plus a FLAG
epitope. The recombinant proteins were puriﬁed from HEK293 transfected
cells using Anti-FLAG M2 aﬃnity gel (Sigma).
Results: Destruction of articular cartilage is a key feature of osteoarthritis.
Aggrecan degradation is followed by irreversible collagen degradation. The
degradation of aggrecan is mainly mediated by the aggrecanases, mul-
tidomain metalloproteinases belonging to the ADAMTS family, in which
ADAMTS4 (aggrecanase-1) and ADAMTS5 (aggrecanase-2) are the most
studied. Although alternative splicing has previously been described in
other ADAMTS members, we here describe and characterise the ﬁrst known
alternative splice variant of ADAMTS4.
RT-PCR on human OA synovial cells using the above primers resulted
in the ampliﬁcation of two products: normal ADAMTS4 and a smaller
product missing 161 base pairs from the 5’ end of exon 9, the result of
alternative splicing in which exon 8 joins to a cryptic 3’ splice site within
exon 9. The protein produced would lack the spacer domain and have a
different C-terminus lacking homologies with the normal human ADAMTS4
C-terminal spacer domain.
The alternatively spliced transcript of ADAMTS4 has been found in cultured
OA synovial cells and in freshly digested OA synovium, but not in human
brain, cervix or lung, or in normal bovine synovium.
The predicted protein synthesized from this alternatively spliced transcript
of ADAMTS4 would lose functions dependent on its spacer domain, like
substrate and matrix binding, and inhibition through ﬁbronectin. Removal
of the spacer domain from ADAMTS4 increases its ability to cleave aggre-
can, and it may well be that this alternatively spliced transcript produces
a protein that is secreted in an active form, capable of cleaving the
Glu373-Ala374 bond in the interglobular domain of aggrecan.
HEK293 cells transfected with a pCEP4 vector containing the cDNA se-
quence of the splice variant of ADAMTS4 produced the corresponding
protein in both the pro and active form. This protein could be found in the
media, but mostly associated with the cells, as conﬁrmed using antibodies
speciﬁc for the splice variant that were produced using synthetic peptides.
Proteins puriﬁed by immunoprecipitation by Anti-FLAG M2 aﬃnity gel
from transfected and untransfected HEK293 cells were analysed using
the ANASpec SensoLyte 520 Aggrecanase I assay kit which showed that
the splice variant had aggrecanase activity comparable to a commercially
available ADAMTS4. The puriﬁed splice variant was also found to cleave
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the Glu373-Ala374 aggrecanase site of aggrecan, as assessed by the neoepi-
tope monoclonal antibody BC3, and again this activity was comparable to
ADAMTS4.
Conclusions: ADAMTS4 is regulated at multiple levels through control of
gene expression, mRNA splicing and protein processing, as well as the
expression of naturally occurring inhibitors. Although alternative splicing
has been described in other ADAMTS family members, we here present the
ﬁrst known splice variant of ADAMTS4, occurring in human OA synovium,
but not in other human tissues tested, or in normal bovine synovium.
It is likely that the changes in the C-terminal domain of the protein
resulting from this alternatively spliced transcript would have changes in
its substrate speciﬁcity. The resulting protein has aggrecanase activity, and
it is possible that the release of low levels of this fully active variant of
ADAMTS4 might be a factor in the slow process of superﬁcial zone aggrecan
loss in osteoarthritis.
002
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1Newcastle Univ., Newcastle upon Tyne, United Kingdom; 2Univ. of East
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Canada; 4Royal Inﬁrmary, Glasgow, United Kingdom; 5Univ. of Strathclyde,
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Purpose: Although matrix metalloproteinases (MMPs) are most strongly
associated with the proteolytic destruction of articular cartilage in os-
teoarthritis (OA), increasing data implicate serine proteinases in such
pathological tissue turnover. We have consistently shown that serine
proteinases interact with the MMPs in the cascades leading to cartilage
collagen resorption. Since collagenolysis is initiated around chondrocytes,
membranous serine proteinases may well contribute to disease. We
therefore screened OA cartilage for serine proteinases including the trans-
membrane serine proteinases (TTSPs) as candidate enzymes with a role in
tissue destruction.
Methods: Serine proteinase gene expression in femoral head cartilage from
either hip OA or fracture to the neck of femur (NOF) patients was assessed
using a custom Taqman low density array. The effect of matriptase on col-
lagen breakdown was determined in cartilage degradation models, whilst
the effect on MMP expression was analyzed by real-time PCR. Activation
of proMMPs was determined using SDS-PAGE and N-terminal sequencing.
Activation of proteinase-activated receptor-2 (PAR-2) was performed in a
synovial perfusion assay in mice.
Results: Matriptase gene expression is signiﬁcantly elevated in cartilage
from OA patients compared to NOF and matriptase is immunolocalized to
OA chondrocytes. We show matriptase can activate proMMP-1 and -3 to its
fully active form. Matriptase alone when added to OA cartilage in explant
culture causes signiﬁcant collagenolysis which is metalloproteinase-
dependent. Matriptase also induces MMP-1, -3 and -13 gene expression
in OA cartilage. Synovial perfusion data conﬁrmed matriptase to activate
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PAR-2 and we demonstrate that matriptase-dependent enhancement of
collagenolysis from OA cartilage is blocked by PAR-2 inhibition.
Conclusions: This study assessed for the ﬁrst time the role of the
transmembrane serine protease matriptase in cartilage destruction in OA.
Elevated matriptase expression in OA, its ability to activate selective
proMMPs as well as induce collagenase expression make this serine pro-
teinase a key initiator and inducer of cartilage destruction in OA. We
propose that the indirect effects of matriptase are PAR-2-mediated and a
more detailed understanding of these mechanisms may highlight important
new therapeutic targets for OA treatment.
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STIMULATION OF MMPS AND CARTILAGE DEGRADATION BY S100A8 AND
S100A9
A.E. van Hummel1,2, H. Zreiqat1, M.M. Smith2, T. Vogl3, J. Roth3,
C.B. Little2
1Tissue Engineering & Biomaterials Unit, Faculty of Engineering, Univ. of
Sydney, Sydney, Australia; 2Raymond Purves Bone & Joint Res. Lab., The
Kolling Inst. of Med. Res., Univ. of Sydney, Royal North Shore Hosp., Sydney,
Australia; 3Inst. of Immunology, Univ. of Muenster, Muenster, Germany
Purpose: Chondrocytes express the calcium binding proteins S100A8 and
S100A9, and both are increased in cartilage in acute and chronic inﬂam-
matory arthritis; however their role in osteoarthritis (OA) is less clear. We
recently demonstrated that chondrocyte S100a8 and S100a9 mRNA were
co-ordinately increased during the onset of experimental OA, but both were
signiﬁcantly down-regulated as OA progressed, although asynchronously
with S100a9 > S100a8. S100A8 and S100A9, but not the heterodimer
(S100A8/S100A9) decrease aggrecan and collagen-2 and induce MMP
and ADAMTS expression in isolated primary articular chondrocytes. The
aim of this study is to determine if similar effect(s) are seen using a
more physiologically-relevant explant culture system and whether MMPs
implicated in late stage cartilage breakdown in OA are activated.
Methods: Ovine articular cartilage explants were cultured for 4 days
in serum-free media ± 10-7M or 10-8M human S100A8, S100A9 or
S100A8/S100A9 (n=3/treatment). Gene expression of S100a8, S100a9, key
cartilage proteins, metalloproteinases and their inhibitors was measured
using real time RT-PCR. Collagen and aggrecan release were measured
as hydroxyproline and glycosaminoglycan (GAG) respectively. Activity of
MMP-2 and MMP-9 were evaluated by gelatin zymography, and MMP-13
using a ﬂuorometric assay.
Results: Aggrecan and collagen-2 expression were not regulated by S100A8
or S100A9. Adamts-1, Adamts-5, Mmp-1, and Mmp-3 mRNA levels were
dose-dependently up-regulated by S100A8 (p<0.01) and S100A9 (p<0.05)
while no change was seen in Mmp-2, Mmp-9, Mmp-14, Timp-1, Timp-2
or Timp-3 mRNA levels. The heterodimer did not regulate expression
of any genes other than Mmp-13. Mmp-13 was increased by S100A8
(≈100 fold; p<0.05) and S100A9 (≈20 fold; p=0.8), but down-regulated
by S100A8/S100A9 (≈25 fold; p<0.05). S100a9 expression was dose-
dependently up-regulated by S100A8 (p<0.01) and S100A9 (p<0.04).
S100a8 expression was low but increased in response to 10-7M S100A8.
There was no collagen release in any cultures. Only in response to 10-7M
S100A8 we observed: increased GAG release (3-fold); activation of pro-
MMP-2; secretion of pro-MMP-9 and pro-MMP-13 (no active MMP-9 or
MMP-13 were detected in any cultures).
Conclusions: These results have conﬁrmed that both S100A8 and S100A9
homodimers are implicated in chondrocyte-mediated cartilage degradation
by increasing expression of MMPs and ADAMTS. Over the short time course
of these experiments S100A8 was more pro-catabolic than S100A9, leading
to greater up-regulation of metalloproteinase mRNA, release of pro-MMP-9
and pro-MMP-13, release and activation of MMP-2, and cartilage aggrecan
loss. Longer-term cultures will determine whether these differences are
maintained and if MMP-driven collagenolysis ultimately occurs. Chondro-
cyte S100a9 and S100a8 expression has been shown to be increased by
IL-1, and the current data also suggests some degree of auto-regulation.
Changes in cartilage explant gene expression by S100A8 and S100A9 largely
matched those in isolated chondrocytes except that in the latter aggrecan
and collagen-2 were signiﬁcantly down-regulated by both homodimers.
Of particular interest was the opposite effect on Mmp-13 expression of
both homodimers versus the heterodimer, implicating the uncoordinated
regulation of the two S100 proteins in cartilage degradation.
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CALPAIN IS INVOLVED IN C-TERMINAL TRUNCATION OF HUMAN
AGGRECAN
A. Struglics, M. Hansson
Lund Univ., Dept. of Orthopedics, Clinical Sci., Lund, Sweden
Purpose: Aggrecan, a structural extracellular matrix protein, is degraded
by proteolysis in joint injuries and in arthritis as an early key event. We
here investigate the possible role of calpain digestion of human aggrecan,
looking at the preferred order of cleavage and analyzing the in vivo content
of calpain generated aggrecan fragments in knee cartilage and synovial
ﬂuid.
Methods: Human aggrecan fragments were puriﬁed by dissociative and as-
sociative CsCl density gradient centrifugations from: OA-pool (adults, n=10)
and normal (youth, n=1) knee cartilage, and from OA-pool (n=47) and acute
inﬂammatory arthritis (n=2) synovial ﬂuid (SF). Cartilage A1D1 fractions
were in vitro digested by m-calpain (EC nr 3.4.22.17; Calbiochem) for
up to 2h. Aggrecan samples were deglycosylated, separated by SDS-PAGE,
transferred to PVDF membranes and probed with antibodies against calpain
generated neo-epitopes (PGVA, GDLS, and EDLS) or against aggrecan G1-
and G3-domains. N- and C-terminal ends not veriﬁed by immunodetection
were estimated using a calculation model.
Results: To study calpain digestion of aggrecan we produced neoepitope
antibodies against the following human aggrecan calpain sites: -PGVA709,
in the keratan sulfate (KS) domain; -GDLS954, 973, 1353, 1431 and -EDLS1411,1472,
in the chondroitin sulfate 1 (CS1) region. Neoepitope speciﬁcity of the
GDLS and PGVA antibodies were conﬁrmed by complete blocking of the
Western blot immunoreactions by the immunogen peptides and by no
blocking using spanning peptides. The EDLS antibody not only recognized
the neoepitope but also the internal sequence. Western blot experiments
of in vitro digested aggrecan (A1D1 from cartilage OA-pool) showed that
calpain cuts human aggrecan in several sites in six separate regions (a–f,
Fig. 1). Time dependent in vitro kinetic studies showed that calpain has a
preferred order of cutting aggrecan, as follows: site-d, -b, -a, -e and site-f.
Due to weak signals it was not possible to get kinetic data on cleavage site-
c. Except that site-a and site-e was exchanged, the same preferred calpain
cleavage order was observed in aggrecan prepared from normal cartilage
as for the OA-pool. Calpain generated aggrecan fragments G1-PGVA (137
kDa), G1-EDLS (310 kDa) and AVPV-GDLS (225 kDa) were also detected in
vivo in OA cartilage, and in similar amounts in normal cartilage. Also, a
ARGS-EDLS (280 kDa) fragment, with an aggrecanase generated N-terminal,
was detected in SF from patients with acute inﬂammatory arthritis but not
in the SF OA-pool.
Figure 1. Six (a–f) calpain cleavage sites/regions were found in human aggrecan. OA car-
tilage (A1D1) was in vitro digested by calpain and fragments were visualized by Western
blot. Illustration of human aggrecan, calpain cleavage sites and calpain in vitro generated
fragments (Mw in kDA).
Conclusions: Our results indicate that calpain cuts human aggrecan in
at least six speciﬁc sites/regions in a preferred order. The results further
suggest that calpain has a function in digesting aggrecan in the CS region
as a step in physiological C-terminal maturation. We can not rule out a role
for calpain digestion of aggrecan also in joint diseases or injuries.
